Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16319
Title: Review article: the practical management of acute severe ulcerative colitis
Austin Authors: Seah, D ;De Cruz, Peter
Affiliation: Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia
Issue Date: Feb-2016
metadata.dc.date: 2016-01-04
Publication information: Alimentary Pharmacology and Therapeutics 2016; 43(4): 482-513
Abstract: BACKGROUND: Acute severe ulcerative colitis (ASUC) is a life-threatening condition for which optimal management strategies remain ill-defined. AIM: To review the evidence regarding the natural history, diagnosis, monitoring and treatment of ASUC to inform an evidence-based approach to management. METHODS: Relevant articles addressing the management of ASUC were identified from a search of MEDLINE, the Cochrane Library and conference proceedings. RESULTS: Of ASUC, 31-35% is steroid-refractory. Infliximab and ciclosporin salvage therapies have improved patient outcomes in randomised controlled trials. Short-term response rates (within 3 months) have ranged from 40% - 54% for ciclosporin and 46-83% for infliximab. Long-term clinical response rates (≥1 year) have ranged from 42%-50% for ciclosporin and 50-65% for infliximab. Short-term and long-term colectomy rates have been respectively: 26-47% and 36-58% for ciclosporin, and 0-50% and 35-50% for infliximab. Mortality rates for ciclosporin and infliximab-treated patients have been: 0-5% and 0-2%, respectively. At present, management challenges include the selection, timing and assessment of response to salvage therapy, utilisation of therapeutic drug monitoring and long-term maintenance of remission. CONCLUSIONS: Optimal management of acute severe ulcerative colitis should be guided by risk stratification using predictive indices of corticosteroid response. Timely commencement and assessment of response to salvage therapy is critical to reducing morbidity and mortality. Emerging pharmacokinetic models and therapeutic drug monitoring may assist clinical decision-making and facilitate a shift towards individualised acute severe ulcerative colitis therapies.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16319
DOI: 10.1111/apt.13491
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26725569
Type: Journal Article
Subjects: Cyclosporine
Antibodies, Monoclonal
Infliximab
Treatment Outcome
Type of Clinical Study or Trial: Reviews/Systematic Reviews
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Jun 22, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.